Last reviewed · How we verify
NCT04681040
Risk Stratification of COVID-19 Using Urine Biomarkers
trial in Covid19 in 964 participants. Status unknown.
14 February 2024
Quick facts
| Lead sponsor | National Center for Global Health and Medicine, Japan |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 964 |
| Start date | 15 September 2020 |
| Primary completion | 14 February 2024 |
| Estimated completion | 25 March 2024 |
| Sites | 7 locations across Denmark, Japan, Philippines, United States, Brazil |
Conditions studied
- Covid19 — all drugs for Covid19 →
- Urine — all drugs for Urine →
- Biomarker — all drugs for Biomarker →
- Acute Respiratory Failure With Hypoxia — all drugs for Acute Respiratory Failure With Hypoxia →
Sponsor
National Center for Global Health and Medicine, Japan — full company profile →
Who can join
20 and older, any sex, with Covid19 or Urine. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and in infected patients, it produces symptoms which range from completely asymptomatic to those expressing severe illness. Early recognition of those developing severe manifestations allows for rapid and appropriate intervention, including admission to intensive care unit and intensive care therapy, such as mechanical ventilation. A current problem is that only limited data exist predicting the clinical course of COVID-19. This study will determine whether non-invasive urinalysis is useful in assessing and predicting the severity or clinical course of patients with COVID-19.
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
-
Repurposing of drugs targeting the cytokine storm induced by SARS-CoV-2.
Ng WH, Tang PCH, Mahalingam S, Liu X. · · 2023 · cited 7× · PMID 36394425 · DOI 10.1111/bph.15987 -
Urinary L-Type Fatty Acid-Binding Protein Predicts Oxygen Demand of COVID-19 in Initially Mild Cases.
Katagiri D, Asai Y, Ohmagari N, Ishikane M, et al · · 2023 · cited 5× · PMID 36910457 · DOI 10.1097/cce.0000000000000873 -
A retrospective cohort study evaluating the predictive value of urinary L-FABP combined with the SOFA score for assessing COVID-19 severity.
Terakawa K, Katagiri D, Asai Y, Ishikane M, et al · · 2025 · cited 1× · PMID 40934210 · DOI 10.1371/journal.pone.0331558 -
Urinary L-Type Fatty Acid-Binding Protein Predicts Oxygen Demand of COVID-19 in Initially Mild Cases
Katagiri D, Asai Y, Ohmagari N, Ishikane M, et al · · 2022 · DOI 10.2139/ssrn.4308767
Verify or expand the search:
- PubMed search for NCT04681040
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Covid19
Currently open trials in the same condition.
- NCT03305341 — Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix · EARLY_PHASE1 · active not recruiting
- NCT06482138 — Dysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation · NA · recruiting
- NCT04924803 — Community Developed Technology-Based Messaging to Increase COVID-19 Vaccine Uptake Among People Who Inject Drugs · NA · active not recruiting
- NCT05013632 — COVID-19 International Drug Pregnancy Registry · recruiting
- NCT04806061 — Urine Alkalinisation in COVID-19 · NA · active not recruiting
Other National Center for Global Health and Medicine, Japan trials
Trials by the same sponsor.
- NCT05366868 — Durable Effect of Imeglimin on the Glycemic Control in Patients With Type 2 Diabetes Mellitus · Phase 4 · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04681040 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by National Center for Global Health and Medicine, Japan
- Last refreshed: 27 March 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04681040.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing